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BACKGROUND
Evidence from a recent trial has shown that the antiinflammatory effects of col-
chicine reduce the risk of cardiovascular events in patients with recent myocardial 
infarction, but evidence of such a risk reduction in patients with chronic coronary 
disease is limited.
METHODS
In a randomized, controlled, double-blind trial, we assigned patients with chronic 
coronary disease to receive 0.5 mg of colchicine once daily or matching placebo. 
The primary end point was a composite of cardiovascular death, spontaneous 
(nonprocedural) myocardial infarction, ischemic stroke, or ischemia-driven coro-
nary revascularization. The key secondary end point was a composite of cardiovas-
cular death, spontaneous myocardial infarction, or ischemic stroke.
RESULTS
A total of 5522 patients underwent randomization; 2762 were assigned to the col-
chicine group and 2760 to the placebo group. The median duration of follow-up 
was 28.6 months. A primary end-point event occurred in 187 patients (6.8%) in 
the colchicine group and in 264 patients (9.6%) in the placebo group (incidence, 
2.5 vs. 3.6 events per 100 person-years; hazard ratio, 0.69; 95% confidence interval 
[CI], 0.57 to 0.83; P<0.001). A key secondary end-point event occurred in 115 pa-
tients (4.2%) in the colchicine group and in 157 patients (5.7%) in the placebo 
group (incidence, 1.5 vs. 2.1 events per 100 person-years; hazard ratio, 0.72; 95% 
CI, 0.57 to 0.92; P = 0.007). The incidence rates of spontaneous myocardial infarc-
tion or ischemia-driven coronary revascularization (composite end point), cardio-
vascular death or spontaneous myocardial infarction (composite end point), ischemia-
driven coronary revascularization, and spontaneous myocardial infarction were 
also significantly lower with colchicine than with placebo. The incidence of death 
from noncardiovascular causes was higher in the colchicine group than in the 
placebo group (incidence, 0.7 vs. 0.5 events per 100 person-years; hazard ratio, 
1.51; 95% CI, 0.99 to 2.31).
CONCLUSIONS
In a randomized trial involving patients with chronic coronary disease, the risk of 
cardiovascular events was significantly lower among those who received 0.5 mg of 
colchicine once daily than among those who received placebo. (Funded by the 
National Health Medical Research Council of Australia and others; LoDoCo2 Aus-
tralian New Zealand Clinical Trials Registry number, ACTRN12614000093684.)
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Despite lifestyle changes and risk-factor reduction, patients with chronic coronary disease remain at high risk for 
acute cardiovascular events.1-3 The central role of 
inflammation in the progression of coronary dis-
ease is well recognized.4,5 The possibility that 
antiinflammatory therapy may improve cardio-
vascular outcomes was first highlighted in the 
Canakinumab Antiinflammatory Thrombosis Out-
come Study (CANTOS) involving patients with a 
history of myocardial infarction and an elevated 
baseline level of C-reactive protein; the results 
showed that the risk of recurrent cardiovascular 
events was lower among those who received 
canakinumab than among those who received 
placebo.6 However, in another trial, a clinical 
benefit with methotrexate was not observed in 
patients with chronic coronary disease.7
Colchicine is an antiinflammatory drug orig-
inally extracted from the autumn crocus (Colchi-
cum autumnale) and was used by the ancient Greeks 
and Egyptians. In contrast to selective inhibition 
of interleukin-1β by canakinumab, colchicine 
has broad cellular effects that include inhibition 
of tubulin polymerization and alteration of leu-
kocyte responsiveness.8-10 In the Colchicine Car-
diovascular Outcomes Trial (COLCOT) involving 
patients who had a myocardial infarction within 
30 days before enrollment, the percentage of those 
who had the composite end point of cardiovascu-
lar death, resuscitated cardiac arrest, myocardial 
infarction, stroke, or urgent hospitalization for 
angina leading to coronary revascularization was 
lower among those who received 0.5 mg of col-
chicine once daily than among those who received 
placebo.11
In an earlier trial of low-dose colchicine 
(LoDoCo) involving patients with chronic coro-
nary disease, we found that the risk of acute 
cardiovascular events was lower among those who 
received 0.5 mg of colchicine once daily than 
among those who did not receive colchicine.12 
This was an open-label trial involving only 532 
patients, and the results required confirmation. 
Accordingly, we conducted an investigator-initi-
ated, randomized, controlled, double-blind, event-
driven trial of low-dose colchicine (LoDoCo2) to 
determine whether 0.5 mg of colchicine once 
daily, as compared with placebo, prevents cardio-
vascular events in patients with chronic coronary 
disease.
Me thods
Trial Design and Oversight
Patient recruitment in the LoDoCo2 trial com-
menced on August 4, 2014, at 13 centers affili-
ated with GenesisCare and the Heart and Vascu-
lar Research Institute of Sir Charles Gairdner 
Hospital in Western Australia. On October 27, 
2016, patient recruitment was expanded with the 
inclusion of 30 centers of the Dutch Network for 
Cardiovascular Research in the Netherlands. 
Enrollment was completed by December 3, 2018. 
The design of the trial has been published previ-
ously.13 The trial protocol, available with the full 
text of this article at NEJM.org, was approved by 
a centralized institutional review board in each 
participating country. An independent data and 
safety monitoring board reviewed cumulative safe-
ty data to safeguard the well-being of the pa-
tients. Full details of the trial organization and a 
list of the trial sites and investigators are provided 
in the Supplementary Appendix, also available at 
NEJM.org.
The academic and clinical investigators de-
signed the study, collected and managed the data, 
performed the statistical analyses, and drafted 
the manuscript. The funders had no role in the 
design or writing of the protocol and statistical 
analysis plan; in the selection or monitoring of 
the participating sites; in the enrollment or fol-
low-up of patients; in the distribution or admin-
istration of the trial drug or placebo; in the col-
lection, storage, analysis, and interpretation of 
the data; in the drafting of the manuscript; or in 
the decision to submit the manuscript for publi-
cation. The trial drug and matching placebo were 
donated by Aspen Pharmacare in Australia and by 
Tiofarma in the Netherlands. The members of 
the steering committee and the trial statisticians 
had unrestricted access to the data and vouch for 
the completeness and accuracy of the data and 
analyses and for the fidelity of the trial to the 
protocol.
Trial Population
Patients 35 to 82 years of age were eligible if they 
had any evidence of coronary disease on invasive 
coronary angiography or computed tomography 
angiography or a coronary-artery calcium score 
of at least 400 Agatston units on a coronary-artery 
calcium scan. Patients were required to have been 
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in a clinically stable condition for at least 6 months 
before enrollment. Patients were not eligible if 
they had moderate-to-severe renal impairment, 
severe heart failure, severe valvular heart disease, 
or known side effects from colchicine. Renal 
function was defined on the basis of the Kidney 
Disease: Improving Global Outcomes (KDIGO) 
Clinical Practice Guideline for Acute Kidney In-
jury.14 A full list of the inclusion and exclusion 
criteria is provided in Table S1 in the Supplemen-
tary Appendix. All the patients provided written 
informed consent to participate.
Run-in, Randomization, and Follow-up
After signing the informed-consent form, eligible 
patients entered an open-label run-in phase for 
1 month, during which time they received 0.5 mg 
of colchicine once daily. At the end of the open-
label run-in phase, the patients who were in sta-
ble condition and had no unacceptable side effects, 
had adhered to the open-label colchicine regimen, 
and remained willing to continue participation 
were randomly assigned in a 1:1 ratio to receive 
0.5 mg of colchicine once daily or matching pla-
cebo. Randomization was performed in a double-
blind manner with the use of a computerized 
algorithm, with stratification according to coun-
try. Clinical evaluations were scheduled before the 
run-in phase, at the time of randomization, and 
at 6-month intervals until the completion of the 
trial. All follow-up assessments were performed 
in person, if possible, or by telephone. The trial 
regimens were continued until the completion of 
the trial. Moreover, clinical follow-up was con-
tinued until the date of trial completion regard-
less of premature discontinuation of colchicine 
or placebo.
End Points
The primary end point was a composite of car-
diovascular death, spontaneous (nonprocedural) 
myocardial infarction, ischemic stroke, or ische-
mia-driven coronary revascularization. Second-
ary end points, which were tested in hierarchical 
fashion, were ranked in the following order: the 
composite of cardiovascular death, spontaneous 
myocardial infarction, or ischemic stroke (key 
secondary end point); the composite of sponta-
neous myocardial infarction or ischemia-driven 
coronary revascularization; the composite of car-
diovascular death or spontaneous myocardial in-
farction; ischemia-driven coronary revasculariza-
tion; spontaneous myocardial infarction; ischemic 
stroke; death from any cause; and cardiovascular 
death. The list of end points, including the pri-
mary end point, was revised several times during 
the trial; the latest and final revision took place 
in January 2020 before the data were unblinded. 
End points were adjudicated by a committee whose 
members were unaware of the trial-group assign-
ments. Additional end points and definitions are 
provided in Table S2.
Statistical Analysis
The trial was designed to accrue a minimum of 
331 primary end-point events and to have a mini-
mum follow-up of 1 year. On the basis of a tar-
get enrollment of 6053 patients in the open-label 
run-in phase, with 5447 undergoing randomiza-
tion after screening, we estimated that the trial 
would have more than 90% power, at a two-sided 
alpha level of 0.05, to detect a 30% lower rate 
(i.e., a hazard ratio of 0.70) of a primary com-
posite end-point event in the colchicine group 
than in the placebo group, assuming a 10% rate 
of discontinuation of colchicine or placebo and an 
annual rate of the primary end point in the con-
trol group of 2.6%. Details of the statistical meth-
ods are provided in the Supplementary Appendix.
The main analysis was based on the time from 
randomization to the first occurrence of any com-
ponent of the primary composite end point. If the 
incidence of the primary end point was signifi-
cantly lower in the colchicine group than in the 
placebo group (P<0.05), then the ranked second-
ary end points were tested in a hierarchical fashion 
at a significance level of 0.05 in order to preserve 
the alpha level. The original protocol did not in-
clude a plan to adjust for multiple testing; hierar-
chical testing was included in the protocol in 
January 2020 before the data were unblinded to 
be consistent with the new guidelines for statis-
tical reporting in the Journal.15
The main analysis was performed according 
to the intention-to-treat principle and included 
all adjudicated end-point events that occurred be-
tween randomization and the end-of-trial date in 
all patients who had undergone randomization, 
regardless of whether they adhered to their as-
signed regimen. Cause-specific hazard ratios in 
the colchicine group, as compared with the pla-
cebo group, and 95% confidence intervals were 
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determined with the use of Cox proportional-
hazards models, stratified according to country. 
If an end-point event had not occurred, follow-up 
data were censored at the time of the competing 
risk event (death from noncardiovascular causes 
or death from any cause, as appropriate) or at the 
end of the trial. Two-sided P values for superiority 
were calculated with the use of log-rank tests, as 
governed by the rules of hierarchical testing. The 
prespecified subgroup analyses were performed 
with the use of the Cox proportional-hazards 
method.
An exploratory sensitivity analysis of the pri-
mary end point in the on-treatment data set was 
also performed. The on-treatment analysis was 
performed in patients who had received at least 
one dose of colchicine or placebo, with additional 
censoring of data 30 days after the last dose was 
received (in addition to the data that were cen-
sored according to the rules for the main inten-
tion-to-treat analysis). Analyses of the primary 
and secondary end points were also performed 
with the use of Fine and Gray subdistribution 
hazard models to account for competing risks.
R esult s
Patients
Among the 6528 patients who provided written 
informed consent and started the open-label run-
in period, 5522 underwent randomization and 
5478 received at least one dose of colchicine or 
placebo (Fig. 1 and Table S3). Among the 1006 
patients (15.4%) who had started the run-in period 
but did not undergo randomization, the most 
common reason was gastrointestinal upset (in 
437 patients).
The baseline characteristics of the patients 
were well balanced between the trial groups (Ta-
ble 1). The mean (±SD) age of the patients was 
66±8.6 years, and 846 (15.3%) were female; 11.7% 
of the patients were current smokers, and 18.2% 
had diabetes. Most patients (4658 [84.4%]) had a 
history of acute coronary syndrome; in 68.2% of 
the patients, the acute event had occurred more 
than 24 months before randomization. At base-
line, the patients were well treated with respect to 
chronic coronary disease, with 99.7% taking an 
antiplatelet agent or an anticoagulant, 96.6% a 
lipid-lowering agent, 62.1% a beta-blocker, and 
71.7% an inhibitor of the renin–angiotensin sys-
tem. Distribution of baseline characteristics ac-
cording to country is provided in Table S4.
Adherence and Follow-up
The date of the last follow-up contact with a pa-
tient was February 17, 2020. The database was 
locked on May 22, 2020. The primary end-point 
status was available for all but one patient. The 
median duration of follow-up was 28.6 months 
(interquartile range, 20.5 to 44.4). In each trial 
group, 10.5% of the patients permanently discon-
tinued colchicine or placebo prematurely (Fig. 1).
Figure 1. Enrollment, Randomization, and Follow-up.
Premature permanent discontinuation of colchicine or placebo was deter-
mined to have occurred if colchicine or placebo was permanently discontin-
ued more than 30 days before the occurrence of a primary end-point event, 
the occurrence of noncardiovascular death, or the regular end-of-trial date, 
whichever came first.
5522 Underwent randomization
6528 Patients were enrolled
in the open-label run-in phase
1006 (15.4%) Did not undergo
randomization
611 Had perceived side
effects
395 Had other reasons
2762 Were assigned to receive
colchicine and were included
in the main analysis
2760 Were assigned to receive
placebo and were included
in the main analysis
44 (1.6%) Had data that were censored
early in the intention-to-treat 
end-point analysis owing to death
from noncardiovascular causes
Median duration of follow-up, 29.0 mo
(IQR, 20.7–45.7)
34 (1.2%) Had data that were censored
early in the intention-to-treat 
end-point analysis: 33 died
from noncardiovascular causes
and 1 was lost to follow-up
Median duration of follow-up, 28.1 mo
(IQR, 20.3–43.5)
289 (10.5%) Permanently discontinued
colchicine prematurely
22 Never received a dose
95 Had perceived side effects
124 Withdrew from the trial
48 Were withdrawn by physician
or had intercurrent illness
291 (10.5%) Permanently discontinued
placebo prematurely
22 Never received a dose
93 Had perceived side effects
125 Withdrew from the trial
51 Were withdrawn by physician
or had intercurrent illness
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Age — yr 65.8±8.4 65.9±8.7
Female sex — no. (%) 457 (16.5) 389 (14.1)
Country — no. (%)
Australia 951 (34.4) 953 (34.5)
The Netherlands 1811 (65.6) 1807 (65.5)
Current smoker — no. (%)† 318 (11.5) 330 (12.0)
Hypertension — no. (%) 1421 (51.4) 1387 (50.3)
Diabetes — no. (%)
Patients receiving any treatment for diabetes 492 (17.8) 515 (18.7)
Patients dependent on insulin 140 (5.1) 147 (5.3)
Renal function — no. (%)‡
Stage 1 or 2 2614 (94.6) 2602 (94.3)
Stage 3a 148 (5.4) 158 (5.7)
Prior acute coronary syndrome — no. (%) 2323 (84.1) 2335 (84.6)
Time since last acute coronary syndrome — no. (%)
≤24 mo 753 (27.3) 726 (26.3)
>24 mo 1570 (56.8) 1609 (58.3)
Prior coronary revascularization — no. (%) 2301 (83.3) 2320 (84.1)
Coronary-artery bypass grafting 319 (11.5) 391 (14.2)
Percutaneous coronary intervention 2100 (76.0) 2077 (75.3)
History of atrial fibrillation — no. (%) 332 (12.0) 317 (11.5)
History of gout — no. (%) 220 (8.0) 226 (8.2)
Medication use — no. (%)
Single antiplatelet therapy 1849 (66.9) 1852 (67.1)
Dual antiplatelet therapy 638 (23.1) 642 (23.3)
Anticoagulant 342 (12.4) 330 (12.0)
No antiplatelet agent or anticoagulant 4 (0.1) 11 (0.4)
Statin 2594 (93.9) 2594 (94.0)
Ezetimibe 551 (19.9) 522 (18.9)
Any lipid-lowering agent 2670 (96.7) 2665 (96.6)
Renin–angiotensin inhibitor 1995 (72.2) 1965 (71.2)
Beta-blocker 1692 (61.3) 1735 (62.9)
Calcium-channel blocker 633 (22.9) 611 (22.1)
*  Plus–minus values are means ±SD.
†  Information on smoking was missing for 21 patients.
‡  Stage 1 refers to an estimated glomerular filtration rate of at least 90 ml per minute per 1.73 m2 of body-surface area 
(normal or high), stage 2 to a rate of 60 to 89 ml per minute per 1.73 m2 (mildly decreased), and stage 3a to a rate 
of 45 to 59 ml per minute per 1.73 m2 (mildly to moderately decreased). Stages are based on the Kidney Disease: 
Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Acute Kidney Injury.14
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Primary and Secondary End Points
The primary composite end-point event of cardio-
vascular death, spontaneous myocardial infarc-
tion, ischemic stroke, or ischemia-driven coronary 
revascularization occurred in 187 patients (6.8%) 
in the colchicine group and in 264 patients (9.6%) 
in the placebo group, with incidence rates of 2.5 
and 3.6 events, respectively, per 100 person-years 
(hazard ratio, 0.69; 95% confidence interval [CI], 
0.57 to 0.83; P<0.001) (Figs. 2 and 3). This treat-
ment effect was consistent in the on-treatment 
analysis (Fig. S1 and Table S5).
A key secondary composite end-point event of 
cardiovascular death, spontaneous myocardial in-
farction, or ischemic stroke occurred in 115 pa-
tients (4.2%) in the colchicine group and in 157 
patients (5.7%) in the placebo group, with inci-
dence rates of 1.5 and 2.1 events, respectively, per 
100 person-years (hazard ratio, 0.72; 95% CI, 
0.57 to 0.92; P = 0.007) (Figs. 2 and 3). In the pre-
specified hierarchical testing of the ranked sec-
ondary end points, the rates of the first five 
secondary end points, including spontaneous myo-
cardial infarction, were significantly lower in the 
colchicine group than in the placebo group 
(Fig. 3). Colchicine did not result in a lower in-
cidence of death from any cause than placebo 
(73 vs. 60 fatalities; incidence, 0.9 vs. 0.8 events, 
respectively, per 100 person-years; hazard ratio, 
1.21; 95% CI, 0.86 to 1.71). Fine and Gray sub-
distribution hazard ratios were virtually identi-
cal to the cause-specific hazard ratios (Table S6).
Additional End Points
A primary composite end-point event as defined 
in the first LoDoCo trial (sudden cardiac death, 
nonfatal out-of-hospital cardiac arrest, acute coro-
nary syndrome [myocardial infarction or unstable 
angina irrespective of revascularization], or ath-
erosclerotic ischemic stroke) occurred in 201 pa-
tients in the colchicine group and in 290 patients 
in the placebo group, with incidence rates of 2.7 
and 4.0 events, respectively, per 100 person-years 
(hazard ratio, 0.67; 95% CI, 0.56 to 0.81) (Fig. 3). 
The results with respect to the occurrence of new 
onset or first recurrence of atrial fibrillation, 
deep-venous thrombosis or pulmonary embolism 
or both, and new-onset diabetes did not differ 
significantly between the trial groups.
Adverse Events
Noncardiovascular deaths occurred more fre-
quently among the patients who received colchi-
Figure 2. Cumulative Incidence of the Primary End Point and the Key 
 Secondary End Point.
Panel A shows the cumulative incidence of the primary composite end 
point of cardiovascular death, myocardial infarction, ischemic stroke, or 
ischemia-driven coronary revascularization, and Panel B shows the cumu-
lative incidence of the key secondary composite end point of cardiovascular 
death, myocardial infarction, or ischemic stroke. The inset in each panel 

























0 12 24 36 48 60
Months since Randomization
B Key Secondary End Point






























































0 12 24 36 48 60







0 12 24 36 48 60






The New England Journal of Medicine 
Downloaded from nejm.org on May 28, 2021. For personal use only. No other uses without permission. 
 Copyright © 2020 Massachusetts Medical Society. All rights reserved. 
n engl j med 383;19 nejm.org November 5, 20201844
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
cine than among those who received placebo, 
with incidence rates of 0.7 and 0.5 events, respec-
tively, per 100 person-years (hazard ratio, 1.51; 
95% CI, 0.99 to 2.31) (Table 2 and Table S7). We 
observed similar rates of cancer diagnosis, hos-
pitalization for infection, hospitalization for pneu-
monia, and hospitalization for a gastrointestinal 
reason in the two trial groups, in both the inten-
tion-to-treat analysis and the on-treatment anal-
ysis (Table 2 and Table S8). Gout occurred in 38 
patients (1.4%) in the colchicine group and in 95 
patients (3.4%) in the placebo group (cumulative 
incidence ratio, 0.40; 95% CI, 0.28 to 0.58). Neutro-
penia and myotoxic effects were uncommon in 
both trial groups. Among the patients from the 
Netherlands, myalgia was reported in 384 (21.2%) 
in the colchicine group and 334 (18.5%) in the 
placebo group (cumulative incidence ratio, 1.15; 
95% CI, 1.01 to 1.31). Dysesthesia was reported 
in 143 patients (7.9%) in the colchicine group and 
in 150 patients (8.3%) in the placebo group (cumu-
lative incidence ratio, 0.95; 95% CI, 0.76 to 1.18).
Subgroup Analyses
The effects of colchicine, as compared with pla-
cebo, on the primary end point were consistent in 
Figure 3. Key End Points and their Components.
The cause-specific hazard ratios were estimated from Cox proportional-hazard regression analysis with death from noncardiovascular 
causes or death from any cause as a competing risk event. Myocardial infarction refers to spontaneous (nonprocedural) myocardial in-
farction. The primary end point in the first low-dose colchicine (LoDoCo) trial was a composite of sudden cardiac death, nonfatal out-of-
hospital cardiac arrest, acute coronary syndrome (myocardial infarction or unstable angina irrespective of revascularization), or athero-
sclerotic ischemic stroke. Any myocardial infarctions refers to either spontaneous or procedural myocardial infarctions. The ratio for 
new-onset diabetes is presented as a cumulative incidence ratio because time-to-event data were not collected. The size of the data 
points is inversely proportional to the precision (the standard error of the log of the hazard ratios or cumulative incidence ratio) of the 
estimates, with larger data points representing more precise estimates. The testing hierarchy for statistical significance was broken at 
the end point of ischemic stroke.
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the prespecified subgroups defined according to 
sex, age (>65 years vs. ≤65 years), smoking status 
(current vs. former or never), hypertension (yes vs. 
no), diabetes (yes vs. no), renal function (stage 1 
or 2 vs. stage 3a [stages are based on the KDIGO 
Clinical Practice Guideline for Acute Kidney In-
jury14]), prior acute coronary syndrome (yes vs. no), 
prior coronary revascularization (yes vs. no), atrial 
fibrillation (yes vs. no), statin dose (high dose vs. 
low or moderate dose), and ezetimibe use (yes vs. 
no). When examined according to country, the 
effect of colchicine, as compared with placebo, on 
the primary end point was directionally consis-
tent but appeared to be quantitatively larger in 
Australia than in the Netherlands (Fig. S2).
Discussion
Among patients with chronic coronary disease, 
most of whom were already receiving proven sec-
ondary prevention therapies, 0.5 mg of colchicine 
once daily resulted in a 31% lower relative risk 
of cardiovascular death, spontaneous myocardi-
al infarction, ischemic stroke, or ischemia-driven 
coronary revascularization (the primary end point) 
than placebo, with a hazard ratio of 0.69. The 
effects of colchicine appeared to be consistent 
across each component of the primary end point 
and all secondary composite end points.
The incidence rates of death from any cause and 
noncardiovascular death were higher with colchi-
cine than with placebo. The observed between-
group difference in the incidence of noncardio-
vascular death was not significant, as shown by 
the 95% confidence interval, and could have been 
due to chance, although the hazard ratio of 1.51 
is of potential concern. The individual causes of 
death (Table S7) do not permit a clear interpreta-
tion of this finding. In the COLCOT trial, non-
cardiovascular death occurred in 23 patients who 
received colchicine and in 20 patients who re-
ceived placebo.11
Among the patients who were enrolled in the 
run-in phase, 15.4% did not undergo random-
ization; the most common reason was gastro-
intestinal upset. Among the patients who had 
successfully completed the run-in phase and had 
undergone randomization, 10.5% in each trial 
group permanently discontinued colchicine or 
placebo prematurely. Our results provide no evi-
dence for a clinically important interaction be-
tween low-dose colchicine and high-dose statins, 















no. of events/100 
person-yrs
Noncardiovascular death 53/2762 (1.9) 0.7 35/2760 (1.3) 0.5 1.51 (0.99–2.31)
Diagnosis of cancer 120/2762 (4.3) 1.6 122/2760 (4.4) 1.6 0.98 (0.76–1.26)
Hospitalization for infection 137/2762 (5.0) 1.8 144/2760 (5.2) 1.9 0.95 (0.75–1.20)
Hospitalization for pneumonia 46/2762 (1.7) 0.6 55/2760 (2.0) 0.7 0.84 (0.56–1.24)
Hospitalization for gastrointestinal reason 53/2762 (1.9) 0.7 50/2760 (1.8) 0.7 1.06 (0.72–1.56)
Gout 38/2762 (1.4) — 95/2760 (3.4) — 0.40 (0.28–0.58)
Neutropenia 4/2762 (0.1) — 3/2760 (0.1) — NR
Myotoxic effects† 3/2762 (0.1) — 3/2760 (0.1) — NR
Myalgia‡ 384/1811 (21.2) — 334/1807 (18.5) — 1.15 (1.01–1.31)
Dysesthesia: numbness or tingling‡ 143/1811 (7.9) — 150/1807 (8.3) — 0.95 (0.76–1.18)
*  Hazard ratios are reported for noncardiovascular death, diagnosis of cancer, hospitalization for infection, hospitalization for pneumonia, 
and hospitalization for gastrointestinal reason; cumulative incidence ratios are reported for gout, myalgia, and dysesthesia because time-to-
event data were not collected for these end points. Cumulative incidence ratios are not reported (NR) for neutropenia and myotoxic effects 
because of the low numbers of events.
†  Rhabdomyolysis occurred in one patient in the colchicine group, who had a full recovery.
‡  Data were collected for the Netherlands cohort only. Reporting of these adverse events was requested by the Medicines Evaluation Board in 
the Netherlands when the trial was expanded to include patients from that country.
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which were used by 3413 patients (61.8%) in the 
trial. Myalgia, which was assessed only in the 
Netherlands cohort, was common in both trial 
groups, although it was reported more frequently 
in the colchicine group.
The CANTOS trial provided evidence suggest-
ing that inflammation plays a causal role in the 
pathogenesis of cardiovascular disease and relat-
ed complications and that interventions to miti-
gate inflammation may reduce the risk of cardio-
vascular events.6 Our results with colchicine are 
consistent with those obtained in the first 
LoDoCo trial and the COLCOT trial and provide 
further support for the potential benefits of anti-
inflammatory therapy in patients with coronary 
disease.11,12 The magnitude of benefit of low-dose 
colchicine in the LoDoCo2 trial is consistent with 
that shown in previous trials of antiinflammatory 
therapy and in previous trials of other secondary 
prevention therapies, including lipid-lowering, 
blood pressure–lowering, and antithrombotic 
therapies, and a benefit was observed in the 
patients who were already receiving therapy with 
these agents.1,3,16-18 Furthermore, the benefits 
emerged early and continued to accrue through-
out the trial, with no suggestion of attenuation 
of benefit during up to 5 years of treatment.
The LoDoCo2 trial has several limitations. 
The percentage of women in the trial was lower 
than would be expected given the percentage of 
women with chronic coronary disease in the gen-
eral population. We did not collect blood-pressure 
or lipid levels at baseline or during the trial, and 
we cannot report outcomes according to risk-
factor control. We did not routinely measure 
C-reactive protein levels or other laboratory indi-
cators of inflammation at baseline, and we can-
not explore the effects of treatment according to 
inflammatory state at baseline. However, the ef-
fects of treatments were consistent across the 
majority of clinical subgroups examined.
The results of our trial show that among pa-
tients with chronic coronary disease, most of 
whom were already receiving proven secondary 
prevention therapies, the occurrence of cardio-
vascular events was significantly lower with low-
dose colchicine than with placebo.
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